A solar-powered airplane finished crossing the United States on Saturday, landing in New York City after flying over the Statue of Liberty during its historic bid to circle the globe, the project team said. The spindly, single-seat experimental aircraft, dubbed Solar Impulse 2, arrived at New York's John F. Kennedy International Airport at about 4 a.m. local time after it took off about five hours beforehand at Lehigh Valley International Airport in Pennsylvania, the team reported on the airplane's website. Such a pleasure to land in New York! For the 14th time we celebrate sustainability," said the project's co-founder Andre Borschberg on Twitter after flying over the city and the Statue of Liberty during the 14th leg of the trip around the globe. The Swiss team flying the aircraft in a campaign to build support for clean energy technologies hopes eventually to complete its circumnavigation in Abu Dhabi, where the journey began in March 2015. The solar cr...
00306-5/assets/gr4.jpg)
The study, at the Institute of Cancer Research in London, took place on 49 men with untreatable cancer. The drug, olaparib, had low overall success, but slowed tumour growth in 88% of patients with specific DNA mutations. Cancer Research UK said the trial was exciting. The future of cancer medicine is treating cancers by their mutated DNA rather than what part of the body they are in. The breast cancer drug Herceptin is already used only in patients with specific mutations. Olaparib targets mutations that change the way DNA is repaired.The trial results, published in the New England Journal of Medicine, showed the drug worked in 14 out of 16 men with such mutations.
Levels of Prostate Specific Antigen, which is produced by tumours, was more than halved and there were also significant falls in the number of prostate cancer cells detected in the blood and in the size of secondary tumours.
Patients responded to the drug for between six months and nearly a year and a half.Professor Johann de Bono, the head of drug development at the Institute of Cancer Research said: "Our trial marks a significant step forward in the treatment of prostate cancer. "I hope it won't be long before we are using olaparib in the clinic to treat prostate cancer."
However, the drugs watchdog in England - the National Institute for Health and Care Excellence - has already rejected olaparib for ovarian cancer on grounds - at £4,000 a month - of cost. Cancer Research UK's Dr Aine McCarthy added: "This trial is exciting because it could offer a new way to treat prostate cancer by targeting genetic mistakes in cancers that have spread.
"The hope is that this approach could help save many more lives in the future."
Comments
Post a Comment